MariMed Q2 FY23 Revenue Grows 10.7% YoY, What About Adjusted EBITDA?
Portfolio Pulse from Vuk Zdinjak
MariMed Inc. reported Q2 FY23 revenue of $36.5 million, a 10.7% YoY increase. However, adjusted EBITDA decreased by 29.4% to $6.3 million. The company also reported a net loss of $935,000 compared to income of $1.9 million in Q2 2022. MariMed's CEO highlighted the company's 14th consecutive quarter of positive adjusted EBITDA and strong balance sheet. The company expects 2023 revenue of at least $150 million and adjusted EBITDA of $32 million to $35 million.
August 04, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
MariMed's Q2 FY23 results show mixed performance with increased revenue but decreased adjusted EBITDA and a net loss. The company's 2023 guidance suggests confidence in future performance.
MariMed's increased revenue indicates growth, but the decrease in adjusted EBITDA and reported net loss may concern investors. However, the company's positive 2023 guidance suggests confidence in its future performance, which could balance out any negative short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100